Long-term follow-up after endovascular treatment in patients with femoropopliteal TASC II class A and B lesion

Abstract

Purpose: The aim of this study was to investigate the outcome following endovascular therapy (EVT) for femoropopliteal (FP) lesion with TransAtlantic Inter-Society Consensus (TASC) II class A and B. Methods: This study was a multicenter retrospective analysis. A total of 2742 consecutive patients with FP disease, 3471limbs were enrolled and 2003 limbs with TASCII A and B lesions were analyzed; 1169 (58.4%) were stenting, 834 (41.6%) were plain old balloon angioplasty (POBA) alone. Results: The mean follow-up term were 4.6±0.1 years. The mean reference vessel diameter was 5.2±1.0 mm and the mean lesion length was 58.7±33.8 mm. Freedom from restenosis was significantly higher in the stent group (85.3%, 69.6% and 59.9% at 1, 3 and 5 years) than that in the POBA group (76.2%, 59.6% and 49.3% at 1, 3 and 5 years; P<0.0001). Freedom from repeated revascularization was also better in the stent group than that in the POBA group (91.2% vs 84.9%, 82.2% vs 75.2% and 76.8% vs 68.0% at 1, 3 and 5 years, respectively; P=0.0002) and the difference in freedom from reocclusion between in the two groups was similar (93.9% vs 92.2%, 86.2% vs 80.5% and 78.6% vs 66.5% at 1, 3 and 5 years, respectively; P=0.006). But limited to lesions with reference vessel diameter (RVD) below 4.5mm, there was no difference in freedom from restenosis between in the two groups (stent vs POBA; 73.0% vs 74.8%, 57.2% vs 53.2% and 46.8% vs 45.4% at 1, 3 and 5 years, P=0.67). Diabetes, hemodialysis, the history of cerebrovascular disease, absence of cilostazol, POBA alone and RVD <4.5mm were found to be independent predictors of freedom from restenosis. ![Figure][1] Freedom from restenosis Conclusions: FP stenting improves the freedom from restenosis, repeated revascularization and reocclusion for TASCII class A and B lesions. [1]: pending:yes